focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
One point I’d note on the “what he’s up to” question from tf…..
…..many corporate mergers fail due to having too many executives for the post-merger number of executive chairs available. I don’t think that will be a problem with Scancell……
After weeks where size of offer was reasonable not much on the offer and not much of a discount. Seller done or maybe wants a higher price?
Https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market.html
Global Fc and Glycoengineered Antibodies Market Size
The global Fc and glycoengineered antibodies market is estimated to be worth US$ 38.8 billion in 2024. Driven by the increasing potential of these engineered antibodies as therapeutic agents, the market is anticipated to grow at a notable rate during the forecast period. Further, in terms of type of engineering, Fc engineered antibodies are likely to capture majority (93%) of the share, followed by glycoengineered antibodies (7%) within the overall market, by 2035.
Frequently Asked Questions
Question 1: What is Fc region engineered antibodies?
Answer: Engineered antibodies, developed by modifying the fragment crystallizable (Fc) region, are termed as Fc region engineered antibodies. The modifications in the Fc region of an antibody have been shown to augment the various effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Question 2: How big is the Fc and glycoengineered antibodies market?
Answer: The Fc and glycoengineered antibodies market size is anticipated to be worth $38.8 billion in 2024.
Question 3: Who are the leading players developing Fc and glycoengineered antibodies?
Answer: Examples of key companies engaged in Fc and glycoengineered antibodies industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, Akesobio, Alexion Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, MacroGenics, MorphoSys, Kyowa Kirin and Xencor.
Question 4: How many Fc and glycoengineered antibodies are currently marketed?
Answer: Around 20 Fc and glycoengineered antibodies are currently marketed across different therapeutic indications.
Question 5: How many companies are currently engaged in the Fc and glycoengineered antibodies market?
Answer: Over 30 companies are currently engaged in the Fc and glycoengineered antibodies industry.
Question 6: Which type of engineering are mainly used to develop Fc and glycoengineered antibodies by various developers?
Answer: At present, majority (93%) of the developers are using Fc engineering to develop Fc and glycoengineered antibodies.
Question 7: Which type of therapy is popular for the development of different Fc and glycoengineered antibodies?
Answer: In the realm of Fc and glycoengineered antibodies, monotherapies are mainly focused, sharing 46% share in the current market.
Question 8: Which target therapeutic area occupies the largest market share of the Fc and glycoengineered antibodies market?
Answer: In 2024, oncological disorders has the largest market share (39%) of the Fc and glycoengineered antibodies market.
Question 9: What is the most common route of administration used for Fc and glycoengineered antibodies?
Answer: Currently, intravenous rou
Thanks Bermuda - interesting possibilities for 'Glycans' and for all 4 of Scancell's platforms . . . . I wonder which of the four will cross the line first, the 'line' being some new commercial action ?
Thanks Johnny. That's good. Noting that Sath is the second of our 2 Executive Directors, he's obviously doing well at Scancell. I wonder what he's up to apart from the routine work ?
I see that with effect from 30 April’24 Keith Green is no longer the Company Secretary and Sath Nirmalananthan is now in that role:-
https://find-and-update.company-information.service.gov.uk/company/06564638/filing-history
Scancell’s website has also been updated to show this:-
https://www.scancell.co.uk/company
Lofas and Team Astute must be livid.
Can't moan and/or offer "balance".
While it's quiet the paper below is worth a read.
CAR T therapy has been hugely successful in blood cancers but nobody has yet managed to crack CAR T for solid tumours. In the link below the researchers are exploring ways of improving CAR T through identification of new solid tumour targets and in particular glycans. A couple of quotes:-
'Carbohydrate antigens often exhibit low immunogenicity and typically elicit T-independent immune responses, posing an obstacle to T-cell engagement. Despite these limitations, the implication of TACAs (tumor-associated carbohydrates antigens) in cancer biology has recently sparked significant interest in their potential as targets for immunotherapy. '
'the large number of experimental approaches to circumvent these difficulties, including many studies that are underway, some already in clinical trials, suggest a bright future for CAR-T therapy for solid tumors. Given the limitations of target antigens, tumor-associated carbohydrates are increasingly being explored as optimal targets for this therapy. These carbohydrates can be highly tumor-specific, while being shared among tumors from different individuals and different tissues of origin; therefore, CAR-T cell therapy may have a promising “sweeter” future.'
https://www.mdpi.com/2073-4409/13/9/725
YAY...some blue 💙
Don’t ofer pointers pointing to nowhere. No need to say anything if there is nothing to say …. Policy adapted by Scancell .
Https://www.independent.co.uk/news/health/covid-vaccine-research-pandemic-uk-b2539136.html
And what do you have to offer Lofas? Confusion, contradiction and FUD perhaps? For someone who has written this share off you seem awfully interested.
I'm pretty sure CW is not a "him" by the way. But there you go go again, shooting your mouth off without a clue.
…and all is under the research banner. Between him and inanaco they contribute 99% of the white noise.
100%
CW as always keeps on posting and creating chats on subjects with no direct connection. What a waste of time and space.
Chelsea what’s the score on this post.?
I'm with C11. It's a tenuous connection at best.
Genmab have such a big pipeline and, if they trial products discovered by other companies, they need to do due diligence on the science but also due diligence on the business and patent aspects of any deal.
Cleaner - you obviously have no idea how many companies Genmab are working with. To think that they are recruiting for senior postions in their organisation with direct relevance to Scancell is ludicrous. It is just general recruitment, the same as any other large pharma recruit all the time - should we post all their vacancies too? However I’ll give you 10 out of 10 for imagination.
We only have one commercial deal and it’s with Genmab on the Glymab platform. Ld has said someone might want exclusivity! We know there is also interest in them taking another Glymab as they are “happy “ with the one that they have
Chelsea I would like to see some of your research on why it’s not relevant as a counter argument?
How many arrows in the quiver ? All for 9 p
https://amp.theguardian.com/society/article/2024/may/06/scientists-create-vaccine-potential-protect-against-future-coronaviruses
Scientists have created a vaccine that has the potential to protect against a broad range of coronaviruses, including varieties that are not yet even known about.
Still in mice !
Hey Ian Sample your behind on news it’s been done before ? Does anyone know how to email him ?
Covidity the link
COVIDITY - Scancell
The first in human (FIH) study is designed to explore the safety, tolerability, and immunogenicity of COVIDITY in healthy adults when administered by needle-free injection. Further information can be found here - A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection
Texas Biomed partners with Scancell to test novel COVID vaccine - Texas Biomed
SAN ANTONIO (Aug. 29, 2023) – A DNA-based vaccine is very effective at protecting against COVID-19, according to a joint preclinical study by Scancell Ltd and Texas Biomedical Research Institute (Texas Biomed) recently published in the Journal of Biotechnology and Biomedicine.
Unlike the Pfizer and Moderna COVID-19 vaccines that use messenger RNA (mRNA) to cue the immune system to produce antibodies, this vaccine platform uses sections of viral DNA to achieve a similar result.
“There is always a need to develop new, or improve on existing vaccines to ensure we have effective tools to counter emerging variants,” says Texas Biomed Innovation Lab Principal Investigator Viraj Kulkarni, PhD. “DNA vaccines are one of the promising alternatives because they are adaptable, simple to generate and effective.”
With respect, I don’t understand the relevance to Scancell of these jobs at Genmab. Of course I understand they are evaluating a Scancell product but the fact they are recruiting for Director roles in their wider organisation, carries no relevance whatsoever to that in my opinion.
Also this is the other role
Director, Legal Counsel (US Market Operations)
Your job will include reviewing, drafting and negotiating agreements for the Market Operations Team, be part of the cross functional group reviewing commercial and scientific materials, provide relevant legal training to sales representatives and others, and provide legal support regarding various types of contracts and engagements
*
* Responsible for legal review of scientific and commercial/marketing material for use in the US Market in close cooperation with Genmab colleagues but also with Genmab collaboration partners.
* Support Marketing and Sales with negotiation, drafting and/or review of commercial agreements
Support Medical Affairs with negotiation, drafting and/or review of agreements (e.g., Advisory Boards) and provide legal review of scientific materials
* Support Market Access by providing legal advice relating to patient support programs, and drafting/ reviewing of applicable agreements (e.g., with service providers for various patient support programs), and providing legal advice relating to arrangements and agreements with various entities in the health care delivery system (including payers, specialty distributors/distributors, GPOs and health care providers and institutions)
Interesting find CW/chilltime.
I found the job link:
https://genmab.wd3.myworkdayjobs.com/en-US/Genmab_Careers_Site/job/Director--Patent-Attorney_R10059
I found these job requirements interesting, though not fully understanding the implications?
"... Your job will include preparing IP strategies, drafting and prosecuting patent applications, reviewing documents prior to publication, ***evaluating third party patent rights***"
"Survey third party patent positions, file relevant actions, and solicit legal opinions against third party patent rights."
Thanks CW, Should help Scancell receive proper notice. IMO
Looks like Genmab beefing up legal teams in USA .
Their KYO time line seems to be working
We also know close relationship with Scancell noted LD was tight lipped
Good posts this morning from
Chill time over on the other side
From jobs
https://www.goinhouse.com
After it announced this week
Director, Legal Counsel (US Market Operations)
* Genmab
* Princeton, NJ
Apr 23
* Director, Patent Attorney
* Genmab
* Princeton, NJ
Apr 15
Recent Genmab news
May 2, 2024 at 5:02 PM CEST
Genmab Announces Financial Results for the First Quarter of 2024
Download
Apr 30, 2024 at 12:40 AM CEST
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Apr 29, 2024 at 10:24 AM CEST
Transactions in Connection with Share Buy-back Program Genmab
Download
Download
Kate Bingham tells NHS to launch experimental cancer vaccine trials with pioneering technology that trains the immune system how to hunt malignant cells
https://www.dailymail.co.uk/health/article-13383755/Former-Covid-jab-tsar-tells-NHS-launch-experimental-cancer-vaccine-trials-pioneering-technology-trains-immune-hunt-malignant-cells.html
“Dr Lennard Lee, a cancer vaccine expert at the University of Oxford, said there are now 12 drug manufacturers testing cancer jabs in the UK. He added: 'We are already gaining the reputation as the best country in the world to develop cancer vaccines.'
This was a post on linked in from a month ago
Robert Watson
•
Clinical Lecturer, University of Oxford | Oncologist | Physician Scientist | Tumour Immunologist
Clinical Lecturer, University of Oxford | Oncologist | Physician Scientist | Tumour Immunologist
1mo •
From a month ago F
Fascinating to attend an investigator meeting for Scancell Ltd's SCOPE study - the second meeting for a
hashtag
#cancervaccine clinical trial in melanoma that I've been to in the space of a few weeks. Great to hear about the immunology underpinning the therapy and enjoyable to interact with other trial teams around the UK. It is really fantastic to be able to offer these cutting-edge clinical trials to our patients at Oxford University Hospitals NHS Foundation Trust and see such rapid ongoing progress in the cancer vaccine space.